Literature DB >> 8884996

Mycoplasma pneumoniae community-acquired pneumonia: a review of 101 hospitalized adult patients.

D Lieberman1, F Schlaeffer, D Lieberman1, S Horowitz, O Horovitz, A Porath.   

Abstract

The features of community-acquired Mycoplasma pneumoniae pneumonia (MP-CAP) were assessed in a prospective study of 101 adults who were hospitalized over the course of 1 year, and were compared with 245 patients who were hospitalized during the same period of time with community-acquired pneumonia (CAP) not caused by M. pneumoniae (non-MP-CAP). MP was the second most common etiology (29.2%) in all CAP patients, and the most common etiological agent (43.2%) in the 17- to 44-year age group. In 65 patients (64.3%) at least one other pathogen was identified for CAP in addition to MP. Although the disease was most prevalent among younger patients, it also involved older and even elderly patients. Compared to non-MP-CAP patients, the severity of disease was significantly lower on average in the MP-CAP group and the length of hospitalization was significantly shorter. Radiologic findings were the same in the two groups. Twenty-two MP-CAP patients recovered without receiving the treatment which is recognized as effective in this disease. We concluded that (1) in most patients with MP-CAP a second CAP pathogen can be identified serologically, (2) MP-CAP cannot be differentiated from non-MP-CAP on the basis of clinical, radiologic, or routine laboratory tests, and (3) in some MP-CAP patients the disease is self-limited, and in these patients the usefulness of standard antibiotic therapy is doubtful.

Entities:  

Mesh:

Year:  1996        PMID: 8884996     DOI: 10.1159/000196557

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  19 in total

1.  In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.

Authors:  M Takahata; M Shimakura; R Hori; K Kizawa; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Molecular detection of Mycoplasma pneumoniae in adults with community-acquired pneumonia requiring hospitalization.

Authors:  J W Dorigo-Zetsma; R P Verkooyen; H P van Helden; H van der Nat; J M van den Bosch
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

3.  Rapid-cycle PCR for detection and typing of Mycoplasma pneumoniae in clinical specimens.

Authors:  F Kong; S Gordon; G L Gilbert
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

4.  Mycoplasma pneumoniae in Community-Acquired Lower Respiratory Tract Infections.

Authors:  Surinder Kumar; Indu Bala Garg; Gulshan Rai Sethi
Journal:  Indian J Pediatr       Date:  2018-01-10       Impact factor: 1.967

5.  Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard".

Authors:  Matthias F C Beersma; Kristien Dirven; Alje P van Dam; Kate E Templeton; Eric C J Claas; Herman Goossens
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

6.  Single-run, parallel detection of DNA from three pneumonia-producing bacteria by real-time polymerase chain reaction.

Authors:  Reinhard B Raggam; Eva Leitner; Jörg Berg; Gerhard Mühlbauer; Egon Marth; Harald H Kessler
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

7.  Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles.

Authors:  I Puljiz; I Kuzman; O Dakovic-Rode; N Schönwald; B Mise
Journal:  Epidemiol Infect       Date:  2005-11-29       Impact factor: 2.451

Review 8.  PCR versus serology for diagnosing Mycoplasma pneumoniae infection: a systematic review & meta-analysis.

Authors:  Lei Zhang; Zhi-Yong Zong; Yan-Bin Liu; Hui Ye; Xiao-Ju Lv
Journal:  Indian J Med Res       Date:  2011-09       Impact factor: 2.375

9.  Mycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ).

Authors:  Heike von Baum; Tobias Welte; Reinhard Marre; Norbert Suttorp; Christian Lück; Santiago Ewig
Journal:  BMC Infect Dis       Date:  2009-05-13       Impact factor: 3.090

10.  Accuracy of IgM antibody testing, FQ-PCR and culture in laboratory diagnosis of acute infection by Mycoplasma pneumoniae in adults and adolescents with community-acquired pneumonia.

Authors:  Jiuxin Qu; Li Gu; Jiang Wu; Jianping Dong; Zenghui Pu; Yan Gao; Ming Hu; Yongxiang Zhang; Feng Gao; Bin Cao; Chen Wang
Journal:  BMC Infect Dis       Date:  2013-04-11       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.